Navigation Links
Azixa in Medical News

EpiCept Corporation Announces Pricing of Public Offering

...hat Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial succ...tions, unknown risks or uncertainties or other risk factors. EPCT-GEN * azixa is a registered trademark of Myriad Genetics, Inc. ...

EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology

...e regulatory approval or achieve significant commercial success, the risk that Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy

...hat Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial succ...tions, unknown risks or uncertainties or other risk factors. EPCT-GEN * azixa is a registered trademark of Myriad Genetics, Inc. ...

EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that EpiCept will not receive any significant payments under ...

EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results

... had initiated a third Phase II clinical trial for azixa in patients with non-small-cell lung cancer that h...d to the brain. Two additional Phase II trials for azixa are also underway in Glioblastoma multiforme and i...of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve si...

EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007

...e, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference

...hat Myriad's development of Azixa(TM) will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial succ...urate assumptions, unknown risks or uncertainties or other risk factors. * azixa is a registered trademark of Myriad Genetics, Inc. EPCT-GEN ...

EpiCept Corporation to Present at the 2007 BIO InvestorForum

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Accelerates Development of Phase I Clinical Study for Cancer

...n metastases due to melanoma. EpiCept's licensing agreement with Myriad for azixa includes milestone payments, and sublicensing income as well as future royalties in the event Myriad's development of azixa continues to progress successfully.
Azixa in Medical Technology

New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines

Study Results Published in Cancer Research TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- EpiCept Corporation today announced the results of scientific studies that (1) demonstrate that Azixa(TM) (MPC-6827) is effective in treating multiple types of human tumors in animal models, (2) rev...

EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Reports Regulatory Progress on Ceplene(TM)

..., if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

... has initiated a third Phase II clinical trial for azixa in patients with non-small-cell lung cancer that h...these patients. Two additional Phase II trials for azixa are underway in primary brain cancer and melanoma ...f Executive Officer. "We believe that the study of azixa in this new indication affords EpiCept with an exp...

Myriad Genetics Presents Azixa's Mode of Action at AACR

... azixa Shows Dual Activity as Vascular Disrupting Agent a...ncer Research (AACR) in Los Angeles, California. azixa has been previously shown to be an inducer of apop...nd subsequent tumor cell death. In recent studies, azixa induced cell death in several primary types of end...

Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR

...ubsequent tumor cell death. Myriad reported that azixa induced cell death in several primary types of a t... human ovarian cancer xenografts, a single dose of azixa induced dramatic tumor blood vessel damage and tum...ation of the substantial clinical opportunity that azixa represents," remarked Jack Talley, President and C...

EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting

...y cause actual results or developments to differ materially include: the risk that Myriad's development of Azixa will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...
Azixa in Biological Technology

EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference

...plene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa will not be successful, the risk that azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our a...

EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

... has initiated a third Phase II clinical trial for azixa in patients with non-small-cell lung cancer that h...these patients. Two additional Phase II trials for azixa are underway in primary brain cancer and melanoma ...f Executive Officer. "We believe that the study of azixa in this new indication affords EpiCept with an exp...
Other Tags
(Date:5/30/2015)... 2015 Cyclist Barry Haarde will ... the World 2015: Piles of Miles” near San ... about hemophilia and encourage individuals to support needy ... Save One Life supports nearly 1,200 impoverished children ... through direct sponsorships, scholarships and micro-enterprise grants. Hemophilia ...
(Date:5/30/2015)... 2015 Key Housing, a top-rated corporate ... announce their June 2015 featured apartment community: 388 Beale ... Francisco, Key Housing is helping those people looking for ... one of the tightest apartment markets in the United ... understandably anyone who requires temporary San Francisco corporate housing ...
(Date:5/30/2015)... “ Milli the Snail ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... engages and educates children. , Interactive mobile games for children ... content and games they are playing are doing much for ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 The IRS ... 26th 2015, announcing that, “criminals used taxpayer-specific data acquired ... on approximately 100,000 tax accounts through IRS’ “Get Transcript” ... birth and street address.” , “You don’t even ... have to think it was only a matter of ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Based in St. ... autism awareness shirts for a couple of months now ... Their latest release, which reads “I’m not misbehaving, I have ... by the parent’s of an autistic child in order to ... autism. , Not only are they raising awareness through the ...
Breaking Medicine News(10 mins):Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 3Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 2Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 3Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 4Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 5Health News:La La Land Shirts Is Busy Spreading Autism Awareness with Complimentary Shipping on Their New Shirt 2
(Date:5/21/2015)... 21, 2015 The Sync Project™ , ... for health, today announced a collaborative partnership with ... will center on collaboration on original research, joint course ... in the collaboration, The Sync Project and BerkleeICE are ... Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... 2015  Technology is rapidly advancing, outpacing enterprises, ability ... cloud. Passwords and their management are soon to be ... specifications such as those developed by the FIDO Alliance™. ... presents for BYOD, COPE, IoT, and mobile payments, the ... In response to the call for ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
Other Contents